Teva Pharmaceutical Industries Limited (ADR)
General ticker "TEVA" information:
- Sector: Health Care
- Industry: Drug Manufacturers - Specialty & Generic
- Capitalization: $20.5B (TTM average)
Teva Pharmaceutical Industries Limited (ADR) follows the US Stock Market performance with the rate: 55.1%.
Estimated limits based on current volatility of 1.4%: low 31.91$, high 32.79$
Factors to consider:
- Earnings expected soon, date: 2026-01-28 bmo
- Total employees count: 36830 (-2.7%) as of 2024
- US accounted for 38.2% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Regulatory and compliance, Drug development risks, Supply chain disruptions, Cybersecurity threats, Economic downturns and volatility
- Current price 37.3% above estimated high
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [14.67$, 25.94$]
- 2025-12-31 to 2026-12-31 estimated range: [12.66$, 23.12$]
Financial Metrics affecting the TEVA estimates:
- Positive: with PPE of 8.9 at the end of fiscal year the price was neutral
- Positive: -5.02 < Operating profit margin, % of -1.80
- Positive: Inventory ratio change, % of -4.82 <= -0.76
- Negative: negative Industry operating cash flow (median)
- Negative: Shareholder equity ratio, % of 13.66 <= 19.35
- Negative: negative Net income
Short-term TEVA quotes
Long-term TEVA plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $15,032.00MM | $15,895.00MM | $16,558.00MM |
| Operating Expenses | $17,229.00MM | $15,462.00MM | $16,861.00MM |
| Operating Income | $-2,197.00MM | $433.00MM | $-303.00MM |
| Non-Operating Income | $-966.00MM | $-1,057.00MM | $-981.00MM |
| R&D Expense | $838.00MM | $953.00MM | $998.00MM |
| Income(Loss) | $-3,163.00MM | $-624.00MM | $-1,284.00MM |
| Taxes | $-643.00MM | $-7.00MM | $676.00MM |
| Other Income(Loss) | $21.00MM | $2.00MM | $1.00MM |
| Profit(Loss)* | $-2,446.00MM | $-559.00MM | $-1,639.00MM |
| Stockholders Equity | $7,804.00MM | $7,506.00MM | $5,373.00MM |
| Inventory | $3,833.00MM | $4,021.00MM | $3,007.00MM |
| Assets | $44,011.00MM | $43,479.00MM | $39,326.00MM |
| Operating Cash Flow | $1,590.00MM | $1,368.00MM | $1,247.00MM |
| Capital expenditure | $548.00MM | $526.00MM | $500.36MM |
| Investing Cash Flow | $656.00MM | $968.00MM | $792.00MM |
| Financing Cash Flow | $-1,487.00MM | $-1,913.00MM | $-1,791.00MM |
| Earnings Per Share** | $-2.20 | $-0.50 | $-1.45 |
| Ordinary share to ADR | 1.00x | 1.00x | 1.00x |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.